Foley Todd
Foley Todd's purchase track record
Foley Todd has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/12/2026 | AKTS | $4.19M | -20.3% | +17.6% | +7.7% |
| 11/2/2021 | TRDA | $2.00M | -59.8% | -74.6% | -9.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
TRDA sees institutional interest from NVIDIA and Merck. The Benzinga report notes that institutional investors linked to NVIDIA and Merck have increased their positions in TRDA. This activity signals growing confidence in the company’s pipeline and may attract additional attention from other investors. The move comes as TRDA trades near the lower end of its 52‑week range, providing a potential entry point for those monitoring the stock.
Transaction History
| AKTS | ▼ Sell | Other | 597,391 | — | 1/12/2026 | View on chart |
| AKTS | ▼ Sell | Other | 2,688,270 | — | 1/12/2026 | View on chart |
| AKTS | ▼ Sell | Other | 716,872 | — | 1/12/2026 | View on chart |
| AKTS | ▲ Buy | Open Market | 232,870 | $4.2M | 1/12/2026 | View on chart |
| TRDA | ▼ Sell | Other | 509,024 | — | 11/2/2021 | View on chart |
| TRDA | ▲ Buy | Open Market | 100,000 | $2.0M | 11/2/2021 | View on chart |
| TRDA | ▼ Sell | Other | 3,816,760 | — | 11/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
AKTS launches second Phase 1b trial for AKY-2519
Aktis Oncology announced the start of a second Phase 1b clinical trial for its AKY-2519 candidate. The trial follows earlier testing and moves the drug further along the development pathway. This progress adds to the company's pipeline activity while the stock remains in a low RSI region, indicating recent price weakness.
AKTS launches second Phase 1b trial for AKY-2519. Aktis Oncology announced the start of a second Phase 1b clinical trial for its AKY-2519 candidate. The trial follows earlier testing and moves the drug further along the development pathway. This progress adds to the company's pipeline activity while the stock remains in a low RSI region, indicating recent price weakness.